Eli Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Comparable A1C Reduction To Daily Insulin Degludec In Phase 3 QWINT-2 Trial; Results Published In NEJM And Presented At EASD 2024; Efsitora Reduced A1C By 1.34% Compared To 1.26% For Insulin Degludec
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's once-weekly insulin efsitora alfa demonstrated comparable A1C reduction to daily insulin degludec in the Phase 3 QWINT-2 trial. The results, published in NEJM and presented at EASD 2024, showed efsitora reduced A1C by 1.34% compared to 1.26% for degludec, with additional benefits in time in range without increased hypoglycemia.
September 10, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's insulin efsitora alfa achieved comparable A1C reduction to insulin degludec in a Phase 3 trial, with additional benefits in time in range. This could enhance Eli Lilly's diabetes product portfolio and potentially boost its stock price.
The successful trial results for efsitora alfa, showing comparable efficacy to a leading insulin product with additional benefits, could strengthen Eli Lilly's position in the diabetes market. This is likely to positively impact investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100